Histopathologic outcome of neoadjuvant image-guided therapy of hepatocellular carcinoma

Journal of Gastrointestinal and Liver Diseases

Volumn 18, Issue 2, 2009, Pages 169-176

  Marin, Horia L ^a   Furth, E Elizabeth ^a   Olthoff, Kim ^a   Shaked, Abraham ^a   Soulen, Michael C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Hepatocellular carcinoma; Liver transplant; Neoadjuvant treatment

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL VIABILITY; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; RADIOFREQUENCY ABLATION; SELECTIVE INTERNAL RADIATION THERAPY; ADJUVANT THERAPY; BRACHYTHERAPY; CATHETER ABLATION; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; LIVER TUMOR; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; PATHOLOGY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADULT; AGED; BRACHYTHERAPY; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 70149089549     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med 2003;139:817-823.
2. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699. (Pubitemid 26079803)
3. United network for organ sharing. Policy 3.6. Http://www.Unos. Org/data/about/viewdatareport .
4. Freeman RB, Edwards EB, Harper AM. Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 2006;6:1416-1421. (Pubitemid 44030324)
5. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-442.
6. Livraghi T, Meloni F, Morabito A, Vettori C. Multimodal imageguided tailored therapy of early and intermediate hepatocellular carcinoma: Long-term survival in the experience of a single radiologic referral center. Liver Transpl 2004;10:S98-106.
7. Pompili M, Mirante VG, Rondinara G, et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 2005;11:1117-1126. (Pubitemid 41341763)
8. Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002;13:S211-221.
9. Ramsey DE KH, Kobeiter H. Chemoembolization of liver tumors: Impact on quality of life. : 93rd Annual Meeting of the American Association for Cancer Research; San Francisco, California, USA 2002,
10. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-151. (Pubitemid 23229140)
11. Bismuth H, Majno PE. Hepatobiliary surgery. J Hepatol 2000;32:208-224.
12. Mazzaferro V, Battiston C, Perrone S, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004;240:900-909. (Pubitemid 39425785)
13. Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology 2001;33:1073-1079. (Pubitemid 32378205)
14. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: Comparison of the proposed ucsf criteria with the Milan criteria and the pittsburgh modifi ed TNM criteria. Liver Transpl 2002;8:765-774. (Pubitemid 35012284)
15. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-1403. (Pubitemid 32496976)
16. Sharma P, Balan V, Hernandez JL, et al. Liver transplantation for hepatocellular carcinoma: the meld impact. Liver Transpl 2004;10:36-41. (Pubitemid 38885890)
17. Yao FY, Bass NM, Nikolai B, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003;9:684-692. (Pubitemid 36874454)
18. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 1999;30:1434-1440.
19. Caturelli E, Siena DA, Fusilli S, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-longterm prospective study. Radiology 2000;215:123-128. (Pubitemid 30190520)
20. Sakamoto I, Aso N, Nagaoki K, et al. Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 1998;18:605-619. (Pubitemid 128467047)
21. Richard HM, 3rd, Silberzweig JE, Mitty HA, Lou WY, Ahn J, Cooper JM. Hepatic arterial complications in liver transplant recipients treated with pretransplantation chemoembolization for hepatocellular carcinoma. Radiology 2000;214:775-779.
22. Graziadei IW, Sandmueller H, Waldenberger P, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003;9:557-563. (Pubitemid 36701690)
23. Kamel IR, Bluemke DA, Ramsey D, et al. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 2003;181:708-710. (Pubitemid 37021839)
24. Wong LL, Tanaka K, Lau L, Komura S. Pre-transplant treatment of hepatocellular carcinoma: assessment of tumor necrosis in explanted livers. Clin Transplant 2004;18:227-234. (Pubitemid 38744844)
25. Majno PE, Adam R, Bismuth H, et al. Infl uence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997;226:688-701; discussion 701-1683
26. Millonig G, Graziadei IW, Freund MC, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007;13:272-279.
27. Ravaioli M, Grazi GL, Ercolani G, et al. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation 2004;78:1780-1786.
28. Liou TC, Shih SC, Kao CR, Chou SY, Lin SC, Wang HY. Pulmonary metastasis of hepatocellular carcinoma associated with transarterial chemoembolization. J Hepatol 1995;23:563-568.
29. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): Safety, tumor response, and survival. J Vasc Interv Radiol 2005;16:1627-1639.
30. Sato K, Lewandowski RJ, Bui JT, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006;29:522-529. (Pubitemid 43822993)
31. Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006;94:572-586. (Pubitemid 44851918)
32. Clark TW, Soulen MC. Chemical ablation of hepatocellular carcinoma. J Vasc Interv Radiol 2002;13:S245-S252.
33. Lencioni R, Bartolozzi C, Caramella D,et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 western patients. Cancer 1995;76:1737-1746.
34. Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995;197:101-108.
35. Lu DS, Yu NC, Raman SS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005;41:1130-1137. (Pubitemid 40593921)
36. Rodriguez-Sanjuan JC, Gonzalez F, Juanco C, et al. Radiological and pathological assessment of hepatocellular carcinoma response to radiofrequency. A study on removed liver after transplantation. World J Surg 2008;32:1489-1494.
37. Goldberg SN, Gazelle GS, Compton CC, Mueller PR, Tanabe KK. Treatment of intrahepatic malignancy with radiofrequency ablation: Radiologic-pathologic correlation. Cancer 2000;88:2452-2463.
38. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228:235-240.
39. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: Complications encountered in a multicenter study. Radiology 2003;226:441-451.
40. Lu DS, Yu NC, Raman SS, et al. Radiofrequency ablation of hepatocellular carcinoma: Treatment success as defi ned by histologic examination of the explanted liver. Radiology 2005;234:954-960.
41. Belghiti J, Carr BI, Greig PD, Lencioni R, Poon RT. Treatment before liver transplantation for hcc. Ann Surg Oncol 2008;15:993-1000.